SCHEMBL6328774

SCHEMBL6328774

OCc1nc2c(ccc3[nH]ccc32)o1

nearest known ligand 0.32

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.32
JAK3 P52333 1/20 0.32
NPC1 O15118 1/20 0.31
CASP3 P42574 1/20 0.30
SENP7 Q9BQF6 1/20 0.30
SENP6 Q9GZR1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3547227 0.79 HTR1A (0.37)
Hydrochloric Acid SCHEMBL3548836 0.77 HTR1A (0.37)
SCHEMBL6324082 0.76 ELANE (0.39) NPC1
SCHEMBL3541504 0.74 MPO (0.41) PIK3CD
SCHEMBL3553010 0.74 PIK3CD (0.39) PIK3CD
Hydrochloric Acid SCHEMBL3546738 0.73 MPO (0.40) PIK3CD
SCHEMBL3547546 0.73 HRH3 (0.38)
Hydrochloric Acid SCHEMBL3548096 0.73 PIK3CD (0.38) PIK3CD
Hydrochloric Acid SCHEMBL3553023 0.72 HRH3 (0.37)
Hydrochloric Acid SCHEMBL3548077 0.70 SMN1; SMN2 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032860-A1 CBI analogs of CC-1065 and the duocarmycins THE SCRIPPS RESEARCH INSTITUTE (US) 2005-02-10 US disclosed
US-20040002528-A1 CBI analogs of CC-1065 and the duocarmycins THE SCRIPPS RESEARCH INSTITUTE (US) 2004-01-01 US disclosed
US-6548530-B1 Antitumor drugs incorporate the 1,2,9,9a-tetrahydrocyclopropa(c)benz(e)indol-4-one (CBI) alkylation subunit; cytotoxic activity THE SCRIPPS RESEARCH INSTITUTE 2003-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002528-A1 CBI analogs of CC-1065 and the duocarmycins DBI, DCK, CCNI PIK3CD 3209/4885JAK3 4801/4885NPC1 1908/4885
US-20050032860-A1 CBI analogs of CC-1065 and the duocarmycins DBI, CCNI, DCK PIK3CD 3031/4885JAK3 4758/4885NPC1 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.